Circular Genomics

Circular Genomics, PharmatrophiX Team on Alzheimer's Biomarkers

San Diego – November 04, 2026 -- Circular Genomics and PharmatrophiX have launched a biomarker collaboration that applies blood-based circular RNA (circRNA) profiling to LM11A-31, PharmatrophiX's first-in-class Alzheimer's candidate, with possible extension across the company's neurodegeneration pipeline.

Planned open-label study is the first test of the circRNA platform

The initial workstream centers on PharmatrophiX's planned open-label Alzheimer's biomarker study of LM11A-31, a small molecule targeting the p75 neurotrophin receptor (p75NTR). Circular Genomics will use its research-use-only CircPath platform to characterize baseline molecular heterogeneity and track pathway-level changes during treatment.

Circular Genomics, Altoida Combine Blood and Digital Biomarkers for Alzheimer's

San Diego – September 22, 2026 -- Circular Genomics and Altoida have entered a collaboration pairing blood-based circular RNA (circRNA) biomarkers with AI-powered digital cognitive testing to accelerate Alzheimer's drug development and build a scalable frontline diagnostic pathway.

Companies design a two-step diagnostic workflow combining digital and molecular data

The alliance links Circular Genomics' CircPathTM circRNA biomarker platform with Altoida's Digital NeuroMarkerTM platform. The proposed workflow starts with a 10-minute, self-administered digital cognitive assessment, followed by a confirmatory circRNA blood test to validate underlying disease biology. The companies say this sequence could reduce dependence on hours-long, specialist-administered neuropsychological batteries and extend Alzheimer's screening into primary care settings.